Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.

IF 6.5 1区 医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2025-01-27 DOI:10.1038/s41541-024-01035-3
Stephene S Meena, Benson K Kosgei, Geofrey F Soko, Cheng Tingjun, Ramadhani Chambuso, Julius Mwaiselage, Ray P S Han
{"title":"Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.","authors":"Stephene S Meena, Benson K Kosgei, Geofrey F Soko, Cheng Tingjun, Ramadhani Chambuso, Julius Mwaiselage, Ray P S Han","doi":"10.1038/s41541-024-01035-3","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor-derived exosomes (TDEs) mediate oncogenic communication, which modifies target cells to reinforce a tumor-promoting microenvironment. TDEs support cancer progression by suppressing anti-tumor immune responses, promoting metastasis, and conferring drug resistance. Thus, targeting TDEs could improve the efficacy of anti-cancer treatments and control metastasis. Current strategies to inhibit TDE-mediated oncogenic communication including drug-based and genetic modification-based inhibition of TDE release and/or uptake, have proved to be inefficient. In this work, we propose TDE surface engineering to express foreign antigens that will trigger life-long anti-TDE immune responses. The possibility of combining the anti-TDE vaccines with other treatments such as chemotherapy, radiotherapy, targeted therapy, and surgery is also explored.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"18"},"PeriodicalIF":6.5000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772600/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-01035-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor-derived exosomes (TDEs) mediate oncogenic communication, which modifies target cells to reinforce a tumor-promoting microenvironment. TDEs support cancer progression by suppressing anti-tumor immune responses, promoting metastasis, and conferring drug resistance. Thus, targeting TDEs could improve the efficacy of anti-cancer treatments and control metastasis. Current strategies to inhibit TDE-mediated oncogenic communication including drug-based and genetic modification-based inhibition of TDE release and/or uptake, have proved to be inefficient. In this work, we propose TDE surface engineering to express foreign antigens that will trigger life-long anti-TDE immune responses. The possibility of combining the anti-TDE vaccines with other treatments such as chemotherapy, radiotherapy, targeted therapy, and surgery is also explored.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开发抗tde疫苗,使癌细胞对治疗和转移控制变得敏感。
肿瘤源性外泌体(TDEs)介导致癌通讯,其修饰靶细胞以加强促进肿瘤的微环境。TDEs通过抑制抗肿瘤免疫反应、促进转移和赋予耐药性来支持癌症进展。因此,靶向TDEs可以提高肿瘤的抗癌疗效,控制肿瘤转移。目前抑制TDE介导的致癌通讯的策略,包括基于药物和基于基因修饰的TDE释放和/或摄取抑制,已被证明是低效的。在这项工作中,我们提出了TDE表面工程来表达外源抗原,这将触发终身抗TDE免疫反应。还探讨了将抗tde疫苗与化疗、放疗、靶向治疗和手术等其他治疗方法联合使用的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
期刊最新文献
Cattle antibodies identify a cross-serotype broadly neutralising foot-and-mouth disease virus epitope. Current status of intranasal and inhaled COVID-19 vaccines. IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner. Vaccine-induced mouse antibodies targeting Plasmodium falciparum PfVFT antigen inhibit blood stages through multiple mechanisms. Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1